Cryoport's Dual-Track Growth Strategy Raises Operational Risk Flags for Investors
Cryoport, the specialized cold-chain logistics provider for cell and gene therapies, faces mounting execution pressure as it manages 701 active clinical trials alongside 19 commercial therapy programs. The company's failure-intolerant logistics model — where a single chain-of-custody breakdown can destroy irreplaceable patient-specific biologics — creates a risk profile that warrants careful scrutiny from investors. With demand for CGT logistics accelerating, the question is whether Cryoport's o
ViaNews Editorial Team (Markets)•